Stroke patients treated intravenously with loberamisal, a novel neuroprotective medication, daily for 10 days and starting ...

Late-Breaking Science Abstract LB 032 - In a phase III clinical trial in China, stroke patients treated intravenously with loberamisal, a novel neuroprotective medication, daily for 10 days starting ...

Cereno Scientific is expanding development of CS014 to treat pulmonary hypertension linked to interstitial lung disease.

In a phase III clinical trial in China, stroke patients treated intravenously with loberamisal, a novel neuroprotective ...

FDA priority review seeks marstacimab label expansion to ≥6 years with inhibitors and ages 6–11 without inhibitors, addressing populations with limited efficacy from factor replacement and high unmet ...

GSK announced that the European Commission has approved Nucala (mepolizumab) as an add-on maintenance treatment for adults in the EU with uncontrolled COPD characterised by raised blood eosinophils ...